EGFR and non-small cell lung carcinoma: Recently, a dual EGFR-VEGF pathway inhibition (e.g., erlotinib and bevacizumab or erlotinib and ramucirumab) has been reported as a promising strategy for patients with EGFR-mutant NSCLC [13].